DNAtriX, Inc. is a Texas-based biotechnology company focused on the development of an oncoloytic virus platform initially for the treatment of malignant glioma.
DNAtriX's lead product, delta24RGD, is a next-generation adenovirus invented by company founder Dr. Juan Fueyo and Dr. Frank McCormick. Phase I clinical trials for delta24RGD began in Q4 of 2008 at MD Anderson Cancer Center.
One Greenway Plaza, Suite 930
Houston TX 77046